Refine
Year of publication
Document Type
- Preprint (600)
- Article (354)
- Doctoral Thesis (1)
- Review (1)
Has Fulltext
- yes (956)
Is part of the Bibliography
- no (956)
Keywords
- Heavy Ion Experiments (18)
- Hadron-Hadron scattering (experiments) (11)
- LHC (9)
- Hadron-Hadron Scattering (7)
- Heavy-ion collision (6)
- ALICE experiment (4)
- Quark-Gluon Plasma (4)
- ALICE (3)
- Heavy Ions (3)
- Jets and Jet Substructure (3)
- pp collisions (3)
- Beauty production (2)
- Charm physics (2)
- Experimental nuclear physics (2)
- Experimental particle physics (2)
- Jets (2)
- Lepton-Nucleon Scattering (experiments) (2)
- Particle and resonance production (2)
- Particle correlations and fluctuations (2)
- Pb–Pb collisions (2)
- Single electrons (2)
- 900 GeV (1)
- ALICE detector (1)
- Anti-nuclei (1)
- Atomic and Molecular Physics (1)
- Biological markers (1)
- Bladder cancer (1)
- Boosted Jets (1)
- Centrality Class (1)
- Centrality Selection (1)
- Checkpoint inhibitor (1)
- Chemokine CCL2 (1)
- Chemokines (1)
- Collective Flow (1)
- Comparison with QCD (1)
- Diagnosis (1)
- Electron-pion identification (1)
- Electroweak interaction (1)
- Elliptic flow (1)
- Femtoscopy (1)
- Fibre/foam sandwich radiator (1)
- HBT (1)
- Hadron production (1)
- Hadron-Hadron Scattering Heavy (1)
- Hadron-hadron interactions (1)
- Heavy Ion Experiment (1)
- Heavy Quark Production (1)
- Heavy flavor production (1)
- Heavy flavour production (1)
- Heavy ions (1)
- Heavy-flavour decay muons (1)
- Heavy-flavour production (1)
- Heavy-ion collisions (1)
- Immunotherapy (1)
- Inclusive spectra (1)
- Intensity interferometry (1)
- Invariant Mass Distribution (1)
- Ionisation energy loss (1)
- Jet Physics (1)
- Jet Substructure (1)
- KOOS IV (1)
- Locally advanced (1)
- Material budget (1)
- Mid-rapidity (1)
- Minimum Bias (1)
- Monte Carlo (1)
- Multi-strange baryons (1)
- Multi-wire proportional drift chamber (1)
- Neural network (1)
- Nivolumab (1)
- Nuclear modification factor (1)
- PD-1 inhibitor (1)
- PYTHIA (1)
- Particle Correlations and Fluctuations (1)
- Particle and Resonance Production (1)
- Pb–Pb (1)
- Production Cross Section (1)
- Properties of Hadrons (1)
- Prostatic neoplasms (1)
- Proton–proton (1)
- QCD (1)
- Quark Gluon Plasma (1)
- Quark Production (1)
- Quark gluon plasma (1)
- Quarkonium (1)
- Radical cystectomy (1)
- Radiotherapy (1)
- Rapidity Range (1)
- Relativistic heavy ion physics (1)
- Relativistic heavy-ion collisions (1)
- Resolution Parameter (1)
- Single muons (1)
- Systematic Uncertainty (1)
- TR (1)
- Time Projection Chamber (1)
- Tracking (1)
- Transition radiation detector (1)
- Transitional cell carcinoma (1)
- Transverse momentum (1)
- Trigger (1)
- Urothelial cancer (1)
- Vector Boson Production (1)
- Xenon-based gas mixture (1)
- dE/dx (1)
- detector (1)
- experimental results (1)
- facial nerve functional outcome (1)
- hearing nerve (1)
- heavy ion experiments (1)
- microsurgical treatment (1)
- quark gluon plasma (1)
- spectra (1)
- vestibular schwannoma (1)
- √sN N = 2.76 TeV (1)
Institute
- Physik (949)
- Frankfurt Institute for Advanced Studies (FIAS) (878)
- Informatik (844)
- Medizin (6)
- Informatik und Mathematik (3)
- Hochschulrechenzentrum (2)
- Neuere Philologien (1)
- Sportwissenschaften (1)
Background: Patients with locally advanced bladder cancer (cT3/4 cN0/N+ cM0) have a poor prognosis despite radical surgical therapy and perioperative chemotherapy. Preliminary data suggest that the combination of radiation and immunotherapy does not lead to excess toxicity and may have synergistic (abscopal) anti-tumor effects. We hypothesize that the combined preoperative application of the PD-1 checkpoint-inhibitor Nivolumab with concomitant radiation therapy of the bladder and pelvic region followed by radical cystectomy with standardized lymphadenectomy is safe and feasible and might improve outcome for patients with locally advanced bladder cancer.
Methods: Study design: “RACE IT” (AUO AB 65/18) is an investigator initiated, prospective, multicenter, open, single arm phase II trial sponsored by Technical University Munich. Study drug and funding are provided by the company Bristol-Myers Squibb.
Study treatment: Patients will receive Nivolumab 240 mg i.v. every 2 weeks for 4 cycles preoperatively with concomitant radiation therapy of bladder and pelvic region (max. 50.4 Gy). Radical cystectomy with standardized bilateral pelvic lymphadenectomy will be performed between week 11–15.
Primary endpoint: Rate of patients with completed treatment consisting of radio-immunotherapy and radical cystectomy at the end of week 15.
Secondary endpoints: Acute and late toxicity, therapy response and survival (1 year follow up).
Main inclusion criteria: Patients with histologically confirmed, locally advanced bladder cancer (cT3/4, cN0/N+), who are ineligible for neoadjuvant, cisplatin-based chemotherapy or who refuse neoadjuvant chemotherapy.
Main exclusion criteria: Patients with metastatic disease (lymph node metastasis outside pelvis or distant metastasis) or previous chemo-, immune- or radiation therapy.
Planned sample size: 33 patients, interim analysis after 11 patients.
Purpose: Surgery of KOOS IV vestibular schwannoma remains challenging regarding the balance of extent of tumor resection (EoR) and functional outcome. Our aim was to evaluate the outcome of surgical resection and define a cut-off value for safe resection with low risk for tumor regrowth of KOOS IV vestibular schwannoma.
Methods: All patients presenting at the authors’ institution between 2000 and 2019 with surgically treated KOOS IV vestibular schwannoma were included. Outcome measures included EoR, facial/hearing nerve function, surgical complications and progression of residual tumor during the median follow-up period of 28 months.
Results: In 58 patients, mean tumor volume was 17.1 ± 9.2 cm3, and mean EoR of 81.6 ± 16.8% could be achieved. Fifty-one patients were available for the follow-up analysis. Growth of residual tumor was observed in 11 patients (21.6%) followed by adjuvant treatment with stereotactic radiosurgery or repeat surgery in 15 patients (29.4%). Overall serviceable hearing preservation was achieved in 38 patients (74.5%) and good facial outcome at discharge was observed in 66.7% of patients, significantly increasing to 82.4% at follow-up. Independent predictors for residual tumor growth was EoR ≤ 87% (OR11.1) with a higher EoR being associated with a very low number of residual tumor progression amounting to 7.1% at follow-up (p=0.008).
Conclusions: Subtotal tumor resection is a good therapeutic concept in patients with KOOS IV vestibular schwannoma resulting in a high rate of good hearing and facial nerve function and a very low rate of subsequent tumor progression. The goal of surgery should be to achieve more than 87% of tumor resection to keep residual tumor progression low.
Hintergrund: Das Vestibularisschwannom ist der dritthäufigste gutartige intrakranielle Tumor. Besonders die Entität des KOOS Grad IV Vestibularisschwannoms stellt auch in der heutigen Zeit eine große Herausforderung für die behandelnden Chirurgen dar. Hierbei gilt es, die Problematik zwischen hochgradiger Tumorresektion und gleichzeitig optimalem Funktionserhalt der beeinträchtigten Nerven zu erkennen und zu bewältigen. Unter diesen Aspekten haben wir in dieser Arbeit versucht, die aktuellen operativen Prinzipien zu bewerten, einzuordnen und eine ideale Grenze für das Resektionsausmaß zu definieren, bei dem sowohl das funktionelle Ergebnis als auch das residuale Tumorwachstum berücksichtigt werden und in einer guten Balance zueinanderstehen.
Methodik: Alle Patienten, die zwischen 2000 und 2019 in der Klinik für Neurochirurgie am Universitätsklinikum Frankfurt mit einem KOOS Grad IV Vestibularisschwannom operativ behandelt wurden, sind in die Studie eingeschlossen worden. Alle Patienten wurden über einen retrosigmoidalen Zugang und unter intraoperativem Neuromonitoring, mit dem Ziel der sub- bis annähernd totalen Tumorresektion und Funktionserhalt des N. facialis, operiert. Die zu untersuchenden Parameter umfassten, neben standardmäßigen Patienten- und Tumormerkmalen, das Resektionsausmaß, das funktionelle Ergebnis des N. facialis, N. trigeminus und der kaudalen Hirnnerven sowie die Hörfunktion. Weiterhin wurden Daten zum operativen Verlauf und zu Komplikationen erhoben und in der Nachsorge wurde regelmäßig das funktionelle Ergebnis anhand klinischer Untersuchungen, sowie das residuale Tumorwachstum durch eine Bildgebung mittels MRT bewertet.
Ergebnisse: In die finale Analyse konnten 58 Patienten eingeschlossen werden. Das mittlere Tumorvolumen betrug 17,1 ± 9,2cm3 und es konnte ein durchschnittliches Resektionsausmaß von 81,6 ± 16,8 % erreicht werden. In die Analyse der Nachsorge konnten aufgrund von fehlenden Daten nur noch 51 Patienten eingeschlossen werden. Die durchschnittliche Nachsorgezeit betrug circa 3 Jahre. In Bezug auf das residuale Tumorwachstum konnte bei 11 Patienten (21,6 %) eine Progression und bei 12 Patienten (23,5 %) eine Regression festgestellt werden. Bei 15 Patienten (29,4 %) wurde postoperativ eine adjuvante Behandlung durchgeführt, entweder durch stereotaktische Bestrahlung oder erneute Operation. Die funktionellen Ergebnisse bei Entlassung zeigten bei 38 Patienten (74,5 %) einen Erhalt der Hörfunktion und bei 34 Patienten (66,7 %) eine gute Funktion des N. facialis. Im Verlauf der Nachsorge verbesserte sich das funktionelle Ergebnis signifikant und stieg bezüglich einer guten Funktion des N. facialis auf 82,4 % an. Außerdem konnte ein ideales Resektionsausmaß von ≤ 87 % (OR 11,1) als unabhängiger Prädiktor für ein residuales Tumorwachstum definiert werden. Dagegen zeigte sich bei einem Resektionsausmaß von > 87 % nur in 7,1 % der Fälle eine Resttumorprogression in der Nachsorge (p = 0,008).
Schlussfolgerung: Die sub- bis annähernd totale Resektion stellt ein angemessenes therapeutisches Verfahren für das KOOS Grad IV Vestibularisschwannom dar und ist besonders bei jeglicher Art von Hirnstammkompressionen die Methode der Wahl. Dieses Verfahren zeigt gute Ergebnisse, vor allem in Bezug auf den Erhalt der Hörfunktion und den Funktionserhalt des N. facialis bei gleichzeitig geringen Raten an Progression des Resttumors. Bei der operativen Versorgung sollte auf ein Resektionsausmaß von > 87 % geachtet werden, um die Wahrscheinlichkeit für einen Tumorprogress möglichst zu reduzieren.
Background: Fumaric acid esters (FAEs; Fumaderm®) are the most frequently prescribed first-line systemic treatment for moderate-to-severe plaque psoriasis in Germany. Risankizumab (Skyrizi®) is a humanized IgG1 monoclonal antibody that specifically binds to the p19 subunit of interleukin 23. Objectives: To compare risankizumab treatment to FAEs in patients with psoriasis. Methods: This phase III randomized, active-controlled, open-label study with blinded assessment of efficacy was conducted in Germany. Patients were randomized (1 : 1) to subcutaneous risankizumab 150 mg (weeks 0, 4 and 16) or oral FAEs at increasing doses from 30 mg daily (week 0) up to 720 mg daily (weeks 8–24). Enrolled patients were adults naïve to and candidates for systemic therapy, with chronic moderate-to-severe plaque psoriasis. Phototherapy was not allowed within 14 days before or during the study. Results: Key efficacy endpoints were met at week 24 for risankizumab (n = 60) vs. FAEs (n = 60) (P < 0·001): achievement of a ≥ 90% improvement in Psoriasis Area and Severity Index (PASI; primary endpoint 83·3% vs. 10·0%), ≥ 100% improvement in PASI (50·0% vs. 5·0%), ≥ 75% improvement in PASI (98·3% vs. 33·3%), ≥ 50% improvement in PASI (100% vs. 53·3%) and a Static Physician’s Global Assessment of clear/almost clear (93·3% vs. 38·3%). The rates of gastrointestinal disorders, flushing, lymphopenia and headache were higher in the FAE group. One patient receiving risankizumab reported a serious infection (influenza, which required hospitalization). There were no malignancies, tuberculosis or opportunistic infections in either treatment arm. Conclusions: Risankizumab was found to be superior to FAEs, providing earlier and greater improvement in psoriasis outcomes that persisted with continued treatment, and more favourable safety results, which is consistent with the known safety profile. No new safety signals for risankizumab or FAEs were observed.
Purpose: Prostate specific antigen is not reliable in diagnosing prostate cancer (PCa), making the identification of novel, precise diagnostic biomarkers important. Since chemokines are associated with more aggressive disease and poor prognosis in diverse malignancies, we aimed to investigate the diagnostic relevance of chemokines in PCa.
Materials and methods: Preoperative and early postoperative serum samples were obtained from 39 consecutive PCa patients undergoing radical prostatectomy. Serum from 15 healthy volunteers served as controls. Concentrations of CXCL12, CXCL13, CX3CL1, CCL2, CCL5, and CCL20 were measured in serum by Luminex. The expression activity of CXCR3, CXCR4, CXCR5, CXCR7, CXCL12, CXCL13, CX3CR1, CXCL1, CCR2, CCR5, CCR6, CCR7, CCL2, and CCL5 mRNA was assessed in tumor and adjacent normal tissue of prostatectomy specimens by quantitative real-time polymerase chain reaction. The associations of these chemokines with clinical and histological parameters were tested.
Results: The gene expression activity of CCL2 and CCR6 was significantly higher in tumor tissue compared to adjacent normal tissue. CCL2 was also significantly higher in the blood samples of PCa patients, compared to controls. CCL5, CCL20, and CX3CL1 were lower in patient serum, compared to controls. CCR2 tissue mRNA was negatively correlated with the Gleason score and grading.
Conclusion: Chemokines are significantly modified during tumorigenesis of PCa, and CCL2 is a promising diagnostic biomarker.
A central motivation for the development of x-ray free-electron lasers has been the prospect of time-resolved single-molecule imaging with atomic resolution. Here, we show that x-ray photoelectron diffraction—where a photoelectron emitted after x-ray absorption illuminates the molecular structure from within—can be used to image the increase of the internuclear distance during the x-ray-induced fragmentation of an O2 molecule. By measuring the molecular-frame photoelectron emission patterns for a two-photon sequential K-shell ionization in coincidence with the fragment ions, and by sorting the data as a function of the measured kinetic energy release, we can resolve the elongation of the molecular bond by approximately 1.2 a.u. within the duration of the x-ray pulse. The experiment paves the road toward time-resolved pump-probe photoelectron diffraction imaging at high-repetition-rate x-ray free-electron lasers.